Avidity Biosciences, Inc. (RNA)

Avidity Biosciences Statistics

Total Valuation

RNA has a market cap or net worth of $5.99 billion. The enterprise value is $4.81 billion.

Market Cap	5.99B
Enterprise Value	4.81B

Important Dates

The last earnings date was Thursday, August 7, 2025, after market close.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

RNA has 128.65 million shares outstanding. The number of shares has increased by 48.40% in one year.

Current Share Class	128.65M
Shares Outstanding	128.65M
Shares Change (YoY)	+48.40%
Shares Change (QoQ)	+0.30%
Owned by Insiders (%)	1.01%
Owned by Institutions (%)	88.80%
Float	98.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	558.55
Forward PS	732.33
PB Ratio	4.72
P/TBV Ratio	5.02
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	448.75
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.26, with a Debt / Equity ratio of 0.00.

Current Ratio	9.26
Quick Ratio	8.82
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -37.76% and return on invested capital (ROIC) is -26.87%.

Return on Equity (ROE)	-37.76%
Return on Assets (ROA)	-24.01%
Return on Invested Capital (ROIC)	-26.87%
Return on Capital Employed (ROCE)	-42.29%
Revenue Per Employee	$27,440
Profits Per Employee	-$1.17M
Employee Count	391
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +6.76% in the last 52 weeks. The beta is 0.95, so RNA's price volatility has been similar to the market average.

Beta (5Y)	0.95
52-Week Price Change	+6.76%
50-Day Moving Average	37.40
200-Day Moving Average	33.59
Relative Strength Index (RSI)	61.88
Average Volume (20 Days)	3,380,045

Short Selling Information

Short Interest	15.67M
Short Previous Month	16.21M
Short % of Shares Out	12.29%
Short % of Float	n/a
Short Ratio (days to cover)	4.31

Income Statement

In the last 12 months, RNA had revenue of $10.73 million and -$455.74 million in losses. Loss per share was -$3.57.

Revenue	10.73M
Gross Profit	-399.71M
Operating Income	-521.78M
Pretax Income	-228.68M
Net Income	-455.74M
EBITDA	-518.74M
EBIT	-521.78M
Loss Per Share	-$3.57

Balance Sheet

The company has $1.18 billion in cash and $5.14 million in debt, giving a net cash position of $1.18 billion or $9.16 per share.

Cash & Cash Equivalents	1.18B
Total Debt	5.14M
Net Cash	1.18B
Net Cash Per Share	$9.16
Equity (Book Value)	1.19B
Book Value Per Share	9.87
Working Capital	1.12B

Cash Flow

In the last 12 months, operating cash flow was -$489.98 million and capital expenditures -$12.72 million, giving a free cash flow of -$502.70 million.

Operating Cash Flow	-489.98M
Capital Expenditures	-12.72M
Free Cash Flow	-502.70M
FCF Per Share	-$3.91

Margins

Gross Margin	n/a
Operating Margin	-4,863.29%
Pretax Margin	-4,247.76%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-48.40%
Shareholder Yield	-48.40%
Earnings Yield	-7.60%
FCF Yield	-8.39%

Analyst Forecast

The average price target for RNA is $68.40, which is 46.84% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$68.40
Price Target Difference	46.84%
Analyst Consensus	Strong Buy
Analyst Count	15
Revenue Growth Forecast (5Y)	160.45%
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RNA has an Altman Z-Score of 13.15.

Altman Z-Score	13.15
Piotroski F-Score	n/a